Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Ruvonoflast

Source date not recordedAnalyse record ↗

Late-stage oral NLRP3 inhibitor being advanced from completed cardiometabolic Phase 2 studies toward a planned PAD Phase 3 program.

Modality
oral tissue- and brain-penetrant small-molecule NLRP3 inflammasome inhibitor
Availability (US)
Two Phase 2a studies completed; Phase 3 PAD study planned for the first half of 2027 and not yet active
Biomarkers
high-sensitivity C-reactive protein; IL-1beta; IL-18; IL-6; fibrinogen; lipoprotein(a); thrombo-inflammatory markers
Hallmark targeted
chronic inflammation, altered intercellular communication, inflammaging
Kind
investigational drug
Clinical trials
NCT07055516 — completed Phase 2a RESOLVE-1; NCT07220629 — completed Phase 2a RESOLVE-2